Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
QuatRx Pharmaceuticals focuses on discovering, licensing, developing, and commercializing therapies primarily targeting endocrine disorders associated with aging. Its lead asset ospemifene has completed Phase III trials for vulvar/vaginal atrophy and was submitted for regulatory approval via its global partner Shionogi Inc. Fispemifene targets testosterone deficiency in men and has reached Phase II. The company also developed becocalcidiol cream for psoriasis through a partnership with Collagenex. A cholesterol-lowering compound QRX‑431 entered early-stage clinical trials. The company’s management team has extensive experience bringing drugs to market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on QuatRx Pharmaceuticals.